<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disorders that cause hyperthyroidism</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disorders that cause hyperthyroidism</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Disorders that cause hyperthyroidism</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Several different disorders can cause hyperthyroidism. It is essential that the correct cause be identified because appropriate therapy depends upon the underlying mechanism of the hyperthyroidism. From a pathogenetic viewpoint, hyperthyroidism results from two different mechanisms that can be distinguished by the findings on the 24-hour radioiodine uptake  (<a class="graphic graphic_table graphicRef76972" href="/z/d/graphic/76972.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroidism with a normal or high radioiodine uptake indicates de novo synthesis of hormone. These disorders can be treated with a thionamide, such as <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a>, which will interfere with hormone synthesis. (See  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroidism with a near absent radioiodine uptake indicates either inflammation and destruction of thyroid tissue with release of preformed hormone into the circulation or an extrathyroidal source of thyroid hormone. Thyroid hormone is not being actively synthesized when hyperthyroidism is due to thyroid inflammation; as a result, thionamide therapy is not useful in these disorders.</p><p></p><p>This topic will review the main causes of hyperthyroidism and outline the therapeutic approach to the less common conditions. The treatment of Graves' disease and toxic nodular goiter and the diagnostic approach to patients with hyperthyroidism are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Hyperthyroidism is more common in women than men (5:1 ratio). The overall prevalence of hyperthyroidism, which is approximately 1.3 percent, increases to 4 to 5 percent in older women [<a href="#rid1">1</a>]. Hyperthyroidism is also more common in smokers [<a href="#rid2">2</a>]. Graves' disease is seen most often in younger women, while toxic nodular goiter is more common in older women.</p><p>In one prospective cohort study of adult women, the overall incidence of Graves' disease was 4.6 per 1000 during 10 years of observation [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3"><span class="h1">HYPERTHYROIDISM WITH A NORMAL OR HIGH RADIOIODINE UPTAKE</span><span class="headingEndMark"> — </span>Hyperthyroidism with a normal or high radioiodine uptake indicates de novo synthesis of hormone. Autoimmune thyroid disease and autonomous thyroid tissue are the major causes of excess new hormone synthesis by the thyroid.</p><p class="headingAnchor" id="H4"><span class="h2">Graves' disease</span><span class="headingEndMark"> — </span>Graves' disease is the most common cause of hyperthyroidism [<a href="#rid4">4</a>]. It is an autoimmune disorder resulting from thyroid-stimulating hormone (TSH)-receptor antibodies (also called thyroid-stimulating immunoglobulins), which stimulate thyroid gland growth and thyroid hormone synthesis and release [<a href="#rid5">5</a>]. Stressful life events may be a risk factor for the disease [<a href="#rid6">6</a>]. Another risk factor may be a relatively high iodine intake [<a href="#rid7">7</a>]. Several drugs have been implicated with the onset of Graves' disease including <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> [<a href="#rid8">8</a>], interferon alfa [<a href="#rid9">9</a>], and <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a> [<a href="#rid10">10</a>]. The autoimmune/inflammatory syndrome induced by adjuvants (ASIA) is a rare cause of Graves' disease, and it has been reported after SARS-CoV-2 vaccination [<a href="#rid11">11,12</a>]. However, analysis of a population-based medical record database of 2.3 million people who received either an inactivated or mRNA coronavirus disease 2019 (COVID-19) vaccine failed to demonstrate a subsequent increase in the diagnosis of Graves' hyperthyroidism [<a href="#rid13">13</a>]. Ophthalmopathy and pretibial myxedema are additional autoimmune manifestations of Graves' disease. (See  <a class="medical medical_review" href="/z/d/html/7841.html" rel="external">"Pathogenesis of Graves' disease"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">"Hashitoxicosis"</span><span class="headingEndMark"> — </span>"Hashitoxicosis" (a neologism that combines "Hashimoto" and "thyrotoxicosis") is a term used to describe rare patients with autoimmune thyroid disease who initially present with hyperthyroidism and a high radioiodine uptake caused by TSH-receptor antibodies similar to Graves' disease [<a href="#rid14">14</a>] (see  <a class="medical medical_review" href="/z/d/html/7854.html" rel="external">"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)"</a>). This is followed by the development of hypothyroidism due to infiltration of the gland with lymphocytes and resultant autoimmune-mediated destruction of thyroid tissue similar to chronic lymphocytic thyroiditis (Hashimoto's thyroiditis).</p><p>The initial therapeutic considerations are similar to those for Graves' disease. However, hypothyroidism may intervene, making further antithyroid therapy unnecessary.</p><p class="headingAnchor" id="H6"><span class="h2">Toxic adenoma and toxic multinodular goiter</span><span class="headingEndMark"> — </span>Toxic adenoma and toxic multinodular goiter are the result of focal and/or diffuse hyperplasia of thyroid follicular cells whose functional capacity is independent of regulation by TSH. Activating somatic mutations of the genes for the TSH receptor have been identified in both toxic adenomas and nodules of toxic multinodular goiters [<a href="#rid15">15-17</a>]. Similarly, activating mutations of the Gs-alpha protein have been identified in toxic adenomas [<a href="#rid15">15,17</a>], but it is uncertain whether they occur in toxic multinodular goiters [<a href="#rid17">17</a>]. Other mutations must also play a role because, in one study, mutations in neither of these genes were found in 15 toxic adenomas [<a href="#rid18">18</a>].</p><p>Mutations of the TSH-receptor gene are most common; they were found in 15 of 31 toxic adenomas in one study [<a href="#rid19">19</a>]. The mutations are usually in the transmembrane domain of the receptor but can be in the extracellular domain [<a href="#rid19">19,20</a>]. The mutant receptors activate adenylyl cyclase in the absence of TSH.</p><p>Toxic multinodular goiter tends to be more common in areas where iodine intake is relatively low [<a href="#rid7">7</a>]. In comparison, the frequency of thyroid adenomas is not related to iodine intake.</p><p class="headingAnchor" id="H7"><span class="h2">Iodine-induced hyperthyroidism</span><span class="headingEndMark"> — </span>Iodine-induced hyperthyroidism can develop after an iodine load, as an example, after administration of contrast agents used for angiography or computed tomography (CT) or iodine-rich drugs such as <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>. However, this is uncommon. In a meta-analysis, the overall estimated prevalence of overt hyperthyroidism after iodine containing contrast was 0.1 percent [<a href="#rid21">21</a>].</p><p>In iodine-induced hyperthyroidism, the radioiodine uptake will be high only if sufficient time has passed for most of the administered iodine to be excreted. By comparison, the uptake will be low if iodine continues to be given or if the original preparation has a long biologic life because, despite the increase in thyroid activity, a recent exogenous iodine load will dilute the radioiodine tracer used to determine the uptake. These disorders are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7844.html" rel="external">"Iodine-induced thyroid dysfunction"</a> and  <a class="medical medical_review" href="/z/d/html/7834.html" rel="external">"Amiodarone and thyroid dysfunction"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Trophoblastic disease and germ cell tumors</span><span class="headingEndMark"> — </span>Hyperthyroidism can occur in women with a hydatidiform mole or choriocarcinoma or in men with testicular germ cell tumors via direct stimulation of the TSH receptor. High levels of isoforms of human chorionic gonadotropin (hCG) with more thyrotropic activity are responsible for the hyperthyroidism [<a href="#rid22">22</a>]. Therapy is directed against the tumor. Thionamides are useful adjunctive therapy since hormone synthesis is occurring within the thyroid. (See  <a class="medical medical_review" href="/z/d/html/7868.html" rel="external">"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes", section on 'hCG-mediated hyperthyroidism'</a> and  <a class="medical medical_review" href="/z/d/html/2995.html" rel="external">"Serum tumor markers in testicular germ cell tumors", section on 'Hyperthyroidism and hCG'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">TSH-mediated hyperthyroidism</span><span class="headingEndMark"> — </span>Hyperthyroidism caused by increased thyroid-stimulating hormone (TSH) production is rare. Two forms, neoplastic and non-neoplastic, are recognized.</p><p>TSH-producing pituitary adenomas are usually macroadenomas by the time of diagnosis, and some are locally invasive [<a href="#rid23">23,24</a>]. Almost all of these patients have a goiter, 40 percent have a visual field defect, and one-third of women have galactorrhea. All patients have high serum thyroid hormone concentrations.</p><p>Therapy is directed at the pituitary tumor. Although not perfect, surgery is reasonably successful (two-thirds are improved or cured), particularly when the serum TSH concentration falls to a low level (&lt;0.2 mU/L) one week after surgery [<a href="#rid25">25</a>]. Radioiodine or thyroid surgery are used only when transsphenoidal surgery, external beam radiotherapy, or somatostatin analogues do not control the hyperthyroidism.</p><p><a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">Octreotide</a> and the longer-acting somatostatin analogue <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">lanreotide</a> have been useful for suppressing TSH production in patients with these adenomas [<a href="#rid24">24,26</a>] and, given preoperatively, may permit more effective surgery of locally invasive tumors [<a href="#rid27">27</a>].</p><p>Further information about the clinical manifestations and treatment of these tumors can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7842.html" rel="external">"TSH-secreting pituitary adenomas"</a>.)</p><p>Non-neoplastic, TSH-mediated hyperthyroidism is due to resistance to the feedback effect of thyroid hormone on pituitary TSH production. This condition is usually due to mutations in the nuclear triiodothyronine (T3) receptor [<a href="#rid23">23,28</a>]. Treatment is rarely satisfactory. T3 [<a href="#rid28">28</a>] and 3,5,3'-triiodothyroacetic acid (a derivative of T3) [<a href="#rid29">29</a>] have been effective in a few patients.</p><p>Another rare form of "TSH-induced" hyperthyroidism results from an activating mutation in the TSH receptor [<a href="#rid30">30,31</a>]. This disorder is transmitted as an autosomal dominant trait, and affected patients are hyperthyroid with appropriate suppression of TSH release.</p><p>Mild TSH-mediated hyperthyroidism after surgery for Cushing syndrome during periods of inadequate corticosteroid replacement has been reported [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Epoprostenol</span><span class="headingEndMark"> — </span>Patients taking <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> (prostaglandin I2) for pulmonary arterial hypertension may develop hyperthyroidism with an elevated radioiodine uptake and negative thyroid-stimulating immunoglobulin levels [<a href="#rid33">33,34</a>]. In one report, 3 of 45 patients developed hyperthyroidism after more than 1.5 years of therapy [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H11"><span class="h1">HYPERTHYROIDISM WITH A NEAR ABSENT RADIOIODINE UPTAKE</span><span class="headingEndMark"> — </span>Hyperthyroidism with a near-absent radioiodine uptake indicates either inflammation and destruction of thyroid tissue with release of preformed hormone into the circulation, or an extrathyroidal source of thyroid hormone. Hyperthyroidism with a low radioiodine uptake can result from thyroiditis, exogenous ingestion of thyroid hormone, or ectopic production of thyroid hormone.</p><p>In patients with increased thyroid activity (de novo synthesis of hormone) who are receiving a continuous exogenous iodine load, eg, kelp tablets containing high concentrations of iodine, or <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, radioiodine uptake will be "artifactually" low due to dilution of the radioiodine tracer. (See <a class="local">'Iodine-induced hyperthyroidism'</a> above and  <a class="medical medical_review" href="/z/d/html/7844.html" rel="external">"Iodine-induced thyroid dysfunction", section on 'Iodine-induced hyperthyroidism'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Thyroiditis</span><span class="headingEndMark"> — </span>The term thyroiditis has been applied to a group of heterogeneous disorders that result in inflammation of thyroid tissue with transient hyperthyroidism due to release of preformed hormone from the colloid space. This initial presentation is followed by a hypothyroid phase and then recovery of thyroid function. The definitions and clinical features of this disorder are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7824.html" rel="external">"Overview of thyroiditis"</a>.)</p><p>When the term subacute thyroiditis is used without modification, it usually refers to subacute granulomatous thyroiditis (de Quervain's thyroiditis), which is a viral or postviral syndrome characterized by fever, malaise, and an exquisitely painful and tender goiter [<a href="#rid35">35</a>] (see  <a class="medical medical_review" href="/z/d/html/7832.html" rel="external">"Subacute thyroiditis", section on 'Clinical features'</a>). In comparison, painless thyroiditis (silent thyroiditis or subacute lymphocytic thyroiditis) is part of the spectrum of autoimmune thyroid disease [<a href="#rid36">36</a>] and has a particular proclivity to occur in the postpartum period (postpartum thyroiditis) [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/7830.html" rel="external">"Painless thyroiditis"</a> and  <a class="medical medical_review" href="/z/d/html/7831.html" rel="external">"Postpartum thyroiditis"</a>.)</p><p>Other causes of thyroiditis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Direct chemical toxicity with inflammation, which is one mechanism by which <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> can cause hyperthyroidism [<a href="#rid38">38</a>] (see  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a>). <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">Sunitinib</a>, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>, and other tyrosine kinase inhibitors may also be associated with a destructive thyroiditis [<a href="#rid39">39,40</a>]. (See  <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Sunitinib'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation thyroiditis, from external radiation or after radioiodine therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs that interfere with the immune system, such as interferon alfa and the checkpoint inhibitors. The programmed death 1 (PD-1) inhibitors (eg, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>) and the combination of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4; eg, <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>) with a PD-1 inhibitor cause a destructive thyroiditis in which hyperthyroidism may more rapidly transition to hypothyroidism than with other causes of destructive thyroiditis [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/7824.html" rel="external">"Overview of thyroiditis", section on 'Drug-induced thyroiditis'</a> and  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Endocrinopathies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A painful destructive thyroiditis possibly due to an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) has been described after inactivated SARS-CoV-2 vaccine [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">Lithium</a>. (See  <a class="medical medical_review" href="/z/d/html/7843.html" rel="external">"Lithium and the thyroid"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Palpation thyroiditis occurring, as an example, during parathyroid surgery.</p><p></p><p>Patients with thyroiditis usually have a radioiodine uptake of less than 1 percent, making radioiodine therapy impossible as well as inappropriate. Thionamides also have no role in treatment, since new hormone is not being synthesized. Therapy consists of beta blockers for symptomatic control and antiinflammatory drugs such as <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, or nonsteroidal antiinflammatory drugs, or, in severe cases, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid43">43</a>]. Ipodate or iopanoic acid, which is currently not available in most countries, is also useful, as it blocks both the conversion of thyroxine (T4) to T3 and reduces the tissue effects of thyroid hormone [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/7877.html" rel="external">"Iodinated radiocontrast agents in the treatment of hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Exogenous and ectopic hyperthyroidism</span><span class="headingEndMark"> — </span>Exogenous or ectopic hyperthyroidism (hyperthyroidism resulting from excess thyroid hormone originating from outside the thyroid gland) can arise from external or internal sources of excess thyroid hormone and can occur in several clinical settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Factitious ingestion of thyroid hormone. (See  <a class="medical medical_review" href="/z/d/html/7840.html" rel="external">"Exogenous hyperthyroidism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute hyperthyroidism from a <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> overdose. This disorder can be ameliorated with beta blockers, drugs that block the 5'-monodeiodinase (such as ipodate) and, in severe cases, plasmapheresis or dialysis. (See  <a class="medical medical_review" href="/z/d/html/7840.html" rel="external">"Exogenous hyperthyroidism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Struma ovarii, in which functioning thyroid tissue is present in an ovarian neoplasm. Treatment consists of ovarian surgery. (See  <a class="medical medical_review" href="/z/d/html/7829.html" rel="external">"Struma ovarii"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Functional thyroid cancer metastases, in which large, bony metastases from widely metastatic follicular thyroid cancer cause symptomatic hyperthyroidism. Treatment may require a variety of approaches including thionamides, radioiodine, surgery, or external radiotherapy. (See  <a class="medical medical_review" href="/z/d/html/7867.html" rel="external">"Follicular thyroid cancer (including oncocytic carcinoma of the thyroid)", section on 'Metastases'</a>.)</p><p></p><p class="headingAnchor" id="H3101368696"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109107.html" rel="external">"Society guideline links: Hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15437.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2178.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2168.html" rel="external">"Patient education: Antithyroid drugs (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2319843358"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Several different disorders can cause hyperthyroidism. It is essential that the correct cause be identified because appropriate therapy depends upon the underlying mechanism of the hyperthyroidism. From a pathogenetic viewpoint, hyperthyroidism results from two different mechanisms that can be distinguished by the findings on the 24-hour radioiodine uptake  (<a class="graphic graphic_table graphicRef76972" href="/z/d/graphic/76972.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperthyroidism with normal or high radioiodine uptake</strong> – The most common cause of hyperthyroidism with a normal or high radioiodine uptake is Graves' disease. Other causes include Hashitoxicosis, toxic adenoma, and toxic multinodular goiter. (See <a class="local">'Hyperthyroidism with a normal or high radioiodine uptake'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperthyroidism with near absent radioiodine uptake</strong> – Hyperthyroidism with a near absent radioiodine uptake can result from thyroid inflammation leading to release of preformed hormone (thyroiditis), exogenous ingestion of thyroid hormone, or ectopic production of thyroid hormone. (See <a class="local">'Hyperthyroidism with a near absent radioiodine uptake'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iodine-induced hyperthyroidism</strong> – Iodine-induced hyperthyroidism can occur after an iodine load in a patient with underlying autonomy in a nodule or nodular goiter. The radioiodine uptake will be high only if sufficient time has passed for the administered iodine to be excreted; iodine uptake is frequently low in patients with iodine-induced hyperthyroidism but is usually not under 1 percent unless the source of iodine is continuous (eg, a daily <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> tablet). (See <a class="local">'Iodine-induced hyperthyroidism'</a> above and  <a class="medical medical_review" href="/z/d/html/7844.html" rel="external">"Iodine-induced thyroid dysfunction"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.</a></li><li><a class="nounderline abstract_t">Asvold BO, Bjøro T, Nilsen TI, Vatten LJ. Tobacco smoking and thyroid function: a population-based study. Arch Intern Med 2007; 167:1428.</a></li><li><a class="nounderline abstract_t">Holm IA, Manson JE, Michels KB, et al. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. Arch Intern Med 2005; 165:1606.</a></li><li><a class="nounderline abstract_t">Brent GA. Clinical practice. Graves' disease. N Engl J Med 2008; 358:2594.</a></li><li><a class="nounderline abstract_t">Davies TF. New thinking on the immunology of Graves' disease. Thyroid Today 1992; 15:1.</a></li><li><a class="nounderline abstract_t">Radosavljević VR, Janković SM, Marinković JM. Stressful life events in the pathogenesis of Graves' disease. Eur J Endocrinol 1996; 134:699.</a></li><li><a class="nounderline abstract_t">Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 1991; 229:415.</a></li><li><a class="nounderline abstract_t">McDermott MT, Burman KD, Hofeldt FD, Kidd GS. Lithium-associated thyrotoxicosis. Am J Med 1986; 80:1245.</a></li><li><a class="nounderline abstract_t">Carella C, Mazziotti G, Amato G, et al. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 2004; 89:3656.</a></li><li><a class="nounderline abstract_t">Daniels GH, Vladic A, Brinar V, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 2014; 99:80.</a></li><li><a class="nounderline abstract_t">Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two Cases of Graves' Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants. Thyroid 2021; 31:1436.</a></li><li><a class="nounderline abstract_t">di Filippo L, Castellino L, Allora A, et al. Distinct Clinical Features of Post-COVID-19 Vaccination Early-onset Graves' Disease. J Clin Endocrinol Metab 2022; 108:107.</a></li><li><a class="nounderline abstract_t">Wong CKH, Lui DTW, Xiong X, et al. Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients. BMC Med 2022; 20:339.</a></li><li><a class="nounderline abstract_t">Fatourechi V, McConahey WM, Woolner LB. Hyperthyroidism associated with histologic Hashimoto's thyroiditis. Mayo Clin Proc 1971; 46:682.</a></li><li><a class="nounderline abstract_t">Duprez L, Hermans J, Van Sande J, et al. Two autonomous nodules of a patient with multinodular goiter harbor different activating mutations of the thyrotropin receptor gene. J Clin Endocrinol Metab 1997; 82:306.</a></li><li><a class="nounderline abstract_t">Parma J, Duprez L, Van Sande J, et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 1997; 82:2695.</a></li><li><a class="nounderline abstract_t">Holzapfel HP, Führer D, Wonerow P, et al. Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters. J Clin Endocrinol Metab 1997; 82:4229.</a></li><li><a class="nounderline abstract_t">Pinducciu C, Borgonovo G, Arezzo A, et al. Toxic thyroid adenoma: absence of DNA mutations of the TSH receptor and Gs alpha. Eur J Endocrinol 1998; 138:37.</a></li><li><a class="nounderline abstract_t">Führer D, Holzapfel HP, Wonerow P, et al. Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab 1997; 82:3885.</a></li><li><a class="nounderline abstract_t">Kopp P, Muirhead S, Jourdain N, et al. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281--&gt;isoleucine) in the extracellular domain of the thyrotropin receptor. J Clin Invest 1997; 100:1634.</a></li><li><a class="nounderline abstract_t">Bervini S, Trelle S, Kopp P, et al. Prevalence of Iodine-Induced Hyperthyroidism After Administration of Iodinated Contrast During Radiographic Procedures: A Systematic Review and Meta-Analysis of the Literature. Thyroid 2021; 31:1020.</a></li><li><a class="nounderline abstract_t">Yoshimura M, Pekary AE, Pang XP, et al. Thyrotropic activity of basic isoelectric forms of human chorionic gonadotropin extracted from hydatidiform mole tissues. J Clin Endocrinol Metab 1994; 78:862.</a></li><li><a class="nounderline abstract_t">Wynne AG, Gharib H, Scheithauer BW, et al. Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients. Am J Med 1992; 92:15.</a></li><li><a class="nounderline abstract_t">Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996; 17:610.</a></li><li><a class="nounderline abstract_t">Losa M, Giovanelli M, Persani L, et al. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996; 81:3084.</a></li><li><a class="nounderline abstract_t">Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993; 119:236.</a></li><li class="breakAll">Golsman, J, Wietecha, K, Rock, J. Thyrotropin-secreting pituitary adenoma: Reduction of tumor size by octreotide therapy into the sellar confines allows surgical cure by transsphenoidal hypophysectomy. 10th Internat Cong Endocrinol, San Francisco, 12-15 June 1996, abst. no. P2-482.</li><li><a class="nounderline abstract_t">Rösler A, Litvin Y, Hage C, et al. Familial hyperthyroidism due to inappropriate thyrotropin secretion successfully treated with triiodothyronine. J Clin Endocrinol Metab 1982; 54:76.</a></li><li><a class="nounderline abstract_t">Beck-Peccoz P, Piscitelli G, Cattaneo MG, Faglia G. Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3'-triiodothyroacetic acid (TRIAC). J Endocrinol Invest 1983; 6:217.</a></li><li><a class="nounderline abstract_t">Duprez L, Parma J, Van Sande J, et al. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 1994; 7:396.</a></li><li><a class="nounderline abstract_t">Farid NR, Kascur V, Balazs C. The human thyrotropin receptor is highly mutable: a review of gain-of-function mutations. Eur J Endocrinol 2000; 143:25.</a></li><li><a class="nounderline abstract_t">Tamada D, Onodera T, Kitamura T, et al. Hyperthyroidism due to thyroid-stimulating hormone secretion after surgery for Cushing's syndrome: a novel cause of the syndrome of inappropriate secretion of thyroid-stimulating hormone. J Clin Endocrinol Metab 2013; 98:2656.</a></li><li><a class="nounderline abstract_t">Chadha C, Pritzker M, Mariash CN. Effect of epoprostenol on the thyroid gland: enlargement and secretion of thyroid hormone. Endocr Pract 2009; 15:116.</a></li><li><a class="nounderline abstract_t">Trapp CM, Elder RW, Gerken AT, et al. Pediatric pulmonary arterial hypertension and hyperthyroidism: a potentially fatal combination. J Clin Endocrinol Metab 2012; 97:2217.</a></li><li><a class="nounderline abstract_t">Volpé R. Subacute (de Quervain's) thyroiditis. Clin Endocrinol Metab 1979; 8:81.</a></li><li><a class="nounderline abstract_t">Nikolai TF, Coombs GJ, McKenzie AK, et al. Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med 1982; 142:2281.</a></li><li><a class="nounderline abstract_t">Roti E, Emerson CH. Clinical review 29: Postpartum thyroiditis. J Clin Endocrinol Metab 1992; 74:3.</a></li><li><a class="nounderline abstract_t">Lambert M, Unger J, De Nayer P, et al. Amiodarone-induced thyrotoxicosis suggestive of thyroid damage. J Endocrinol Invest 1990; 13:527.</a></li><li><a class="nounderline abstract_t">Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 2008; 69:669.</a></li><li><a class="nounderline abstract_t">Ahmadieh H, Salti I. Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment. Biomed Res Int 2013; 2013:725410.</a></li><li><a class="nounderline abstract_t">Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol 2018; 4:173.</a></li><li><a class="nounderline abstract_t">İremli BG, Şendur SN, Ünlütürk U. Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Postvaccination ASIA Syndrome. J Clin Endocrinol Metab 2021; 106:2600.</a></li><li><a class="nounderline abstract_t">Volpé R. The management of subacute (DeQuervain's) thyroiditis. Thyroid 1993; 3:253.</a></li><li><a class="nounderline abstract_t">Arem R, Munipalli B. Ipodate therapy in patients with severe destruction-induced thyrotoxicosis. Arch Intern Med 1996; 156:1752.</a></li></ol></div><div id="topicVersionRevision">Topic 7871 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836274" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620538" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tobacco smoking and thyroid function: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043678" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18550875" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical practice. Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : New thinking on the immunology of Graves' disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8766938" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Stressful life events in the pathogenesis of Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2040867" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3755288" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lithium-associated thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292282" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24170099" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33858208" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Two Cases of Graves' Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36130234" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Distinct Clinical Features of Post-COVID-19 Vaccination Early-onset Graves' Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36229814" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5171000" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hyperthyroidism associated with histologic Hashimoto's thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989278" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Two autonomous nodules of a patient with multinodular goiter harbor different activating mutations of the thyrotropin receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253356" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398745" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9461313" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Toxic thyroid adenoma: absence of DNA mutations of the TSH receptor and Gs alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360556" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9294132" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281--&gt;isoleucine) in the extracellular domain of the thyrotropin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33327840" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prevalence of Iodine-Induced Hyperthyroidism After Administration of Iodinated Contrast During Radiographic Procedures: A Systematic Review and Meta-Analysis of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8157712" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Thyrotropic activity of basic isoelectric forms of human chorionic gonadotropin extracted from hydatidiform mole tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1346235" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8969971" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Thyrotropin-secreting pituitary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8768879" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8323093" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8323093" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6798060" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Familial hyperthyroidism due to inappropriate thyrotropin secretion successfully treated with triiodothyronine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6619530" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3'-triiodothyroacetic acid (TRIAC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7920658" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10870027" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The human thyrotropin receptor is highly mutable: a review of gain-of-function mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23671315" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hyperthyroidism due to thyroid-stimulating hormone secretion after surgery for Cushing's syndrome: a novel cause of the syndrome of inappropriate secretion of thyroid-stimulating hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289321" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of epoprostenol on the thyroid gland: enlargement and secretion of thyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22622024" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pediatric pulmonary arterial hypertension and hyperthyroidism: a potentially fatal combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/371876" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Subacute (de Quervain's) thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6897348" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727826" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical review 29: Postpartum thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2258582" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Amiodarone-induced thyrotoxicosis suggestive of thyroid damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18394019" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24282820" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973656" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34043800" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Postvaccination ASIA Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8257868" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The management of subacute (DeQuervain's) thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8694676" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Ipodate therapy in patients with severe destruction-induced thyrotoxicosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
